NewAmsterdam Pharma (NASDAQ:NAMSW) Sees Significant Drop in Short Interest

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 41 shares, a drop of 83.2% from the January 15th total of 244 shares. Based on an average daily volume of 459 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 459 shares, the days-to-cover ratio is currently 0.1 days.

NewAmsterdam Pharma Trading Up 2.9%

NASDAQ:NAMSW traded up $0.65 during midday trading on Thursday, reaching $23.15. 700 shares of the company traded hands, compared to its average volume of 979. The company has a fifty day moving average price of $23.09 and a 200 day moving average price of $20.88. NewAmsterdam Pharma has a twelve month low of $5.45 and a twelve month high of $29.99.

Institutional Investors Weigh In On NewAmsterdam Pharma

An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMSW) by 1.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,000 shares of the company’s stock after acquiring an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 at the end of the most recent reporting period.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.